STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more

Eli Lilly's gene therapy reduced cholesterol by 62% in a Phase 1 trial, with no serious adverse events. The company acquired the therapy through its $1 billion buyout of Verve Therapeutics and plans Phase 2 trials. Lilly also agreed to buy three vaccine developers (Curevo, LimmaTech Biologics, and Vaccine Company) in deals totaling up to $4 billion, expanding its focus on infectious diseases.